Fabiani F, De Vincentis N, Staffilano A
Servizio di Medicina Nucleare, Ospedale Civile G. Mazzini, Teramo, Italy.
Diabete Metab. 1995 Dec;21(5):360-4.
The aim of the present study was to investigate the influence of Tolrestat, an aldose-reductase inhibitor, on both oesophageal and cholecystic motility in Type-2 diabetic patients with asymptomatic diabetic neuropathy. Sixty-six patients were randomly assigned to receive Tolrestat 200 mg once daily (33 patients) or were left without specific treatment (33 patients) for 12 months. Efficacy and safety evaluation were done at 4.5 and 12 months by persons blinded to the patient treatment regimen. Scintigraphic evaluation of oesophageal motility showed significant changes in transit time for Tolrestat at 12 months (p < 0.001). There was no significant effect of Tolrestat on cholecystic function in cholecystography, although diabetic patients taking Tolrestat showed a trend toward improvement. The vibration perception threshold at two sites of the dominant leg improved by at least 3 volts in the Tolrestat group and remained unchanged or slightly deteriorated in the control group. Tendon reflexes and blood pressure fall after standing were improved in the Tolrestat group. In conclusion, one-year treatment with Tolrestat significantly improved oesophageal motility and vibration perception in Type-2 diabetic patients with asymptomatic diabetic neuropathy.
本研究的目的是调查醛糖还原酶抑制剂托瑞司他对2型无症状糖尿病神经病变患者食管和胆囊运动功能的影响。66例患者被随机分为两组，一组33例患者每日一次服用200毫克托瑞司他，另一组33例患者不接受特殊治疗，为期12个月。由对患者治疗方案不知情的人员在4.5个月和12个月时进行疗效和安全性评估。食管运动功能的闪烁扫描评估显示，12个月时托瑞司他组的通过时间有显著变化（p < 0.001）。在胆囊造影中，托瑞司他对胆囊功能无显著影响，尽管服用托瑞司他的糖尿病患者有改善趋势。托瑞司他组优势腿两个部位的振动觉阈值至少提高了3伏，而对照组则保持不变或略有恶化。托瑞司他组患者站立后的腱反射和血压下降情况有所改善。总之，对2型无症状糖尿病神经病变患者进行为期一年的托瑞司他治疗可显著改善食管运动功能和振动觉。
